Posted by Michael Wonder on 03 May 2021
Amphastar Pharmaceuticals receives FDA approval for morphine sulphate injection
3 May 2021 - Amphastar Pharmaceuticals announced that the U.S. FDA approved the Company’s abbreviated new drug application for morphine sulphate injection 1mg/mL in the 30 mL Pump-Jet pre-filled syringe system.
It is indicated for the management of pain severe enough to require use of an opioid analgesic by patient-controlled analgesia, only for use with a compatible Alaris infusion device, and for which alternative treatments are inadequate.
